U.S. flag An official website of the United States government
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Niche Pharmaceuticals, Inc - 553911 - 07/08/2019
  1. Warning Letters

RESPONSE LETTER

Niche Pharmaceuticals, Inc


Company:
Niche Pharmaceuticals, Inc

580 Commerce St.
Ste. 100
Southlake, TX 76092-9156
United States

817-421 -2777
Recipient:
Dana Lewis
Compliance Officer

United States


Dear Ms. Lewis,

This letter is a follow-up to our discussion regarding the Warning Letter received by Niche Pharmaceuticals, Inc. on July 19, 2018. Case 553911. Pursuant to the Agency's request Niche Pharmaceuticals, Inc. has reformulated its product Mag-Tab SR to remove yellow dye #10 from the formulation. The caplet now contains "(b)(4) white" which is approved for dietary supplements as a colorant. As allowed by the CFSAN, all existing yellow caplets were sold by about April 1, 2019. All current inventory and sales are now yellow dye free and are white coated caplets.

Further to the Warning Letter, we edited our website shortly after receiving the letter to remove the few items cited as drug claims in the Metabolic section as well as a few testimonials.

As such we are requesting the FDA to update their action with a follow-up letter stating that Niche Pharmaceuticals, Inc. is "in compliance" with the stated Warning Letter demands.

Sincerely,
/S/
Stephen F. Brandon Sr. - CEO
Niche Pharmaceuticals, Inc.